Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors

This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN818 with Olaparib in adult patients with locally advanced or metastatic solid tumors

Participants needed: 110
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Hangzhou SynRx Therapeutics Biomedical Technology Co., LtdUpdated: Sep 5, 2025Locations: 2
Eligibility criteria

Having signed the written Informed Consent Form (ICF); [+8]

Previous or current use of DNA Polymerase Theta (POLQ) inhibitors; [+7]

Read more
Status: Not yet recruiting

Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors

This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN608 as monotherapy in adult patients with advanced solid tumors

Participants needed: 105
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Hangzhou SynRx Therapeutics Biomedical Technology Co., LtdUpdated: Jul 28, 2025Locations: 2
Eligibility criteria

Having signed the written Informed Consent Form (ICF); [+8]

Previous or current use of Poly (ADP) ribose glycohydrolase (PARG) inhibitors; [+9]

Read more
Status: Recruiting

Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors

This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN818 as monotherapy in adult patients with advanced solid tumors

Participants needed: 30
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Hangzhou SynRx Therapeutics Biomedical Technology Co., LtdUpdated: Jul 20, 2025Locations: 2
Eligibility criteria

Having signed the written Informed Consent Form (ICF); [+8]

Previous or current use of POLQ inhibitors; [+8]

Read more